Antibody Functional Assays

Antibody and T-cell based immunotherapy strategies have become increasingly important in disease treatments that harness the human immune system. The evaluation of therapeutics’ impact on the immune system is critical in the assessment of efficacy, safety, and commercial value.

Curia offers a variety of assays for characterizing Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC) activity with candidate therapeutics.

  • Standard ADCC assay configuration includes Thaw-and-Use effector and target cells that provides reliable function, elimination of donor to donor PBMC/NK variation and quick turnaround. Readout is by luminescence reporter engagement that is suitable for screening large numbers of therapeutics.
  • Client-Specific target cells can be incorporated at an additional cost for development and optimization workflows.
  • Standard CDC assay configuration includes appropriate target cells as specified by the client and purified human complement. Daudi cells and Rituximab are used as a positive control for the assay. Readout is via cell viability by luminescence. Additional charges for screening of target cells by Flow Cytometry.
  • Custom configurations available for additional development and optimization cost.

Curia offers a variety of assays for characterizing T-cell activity with candidate therapeutics.

  • T-cell activation and proliferation assays include stimulation with staphylococcal enterotoxin B (SEB), cytomegalovirus (CMV) recall antigen, and anti-CD3 antibodies.
  • Assay readouts include cytokine measurement by Flow Cytometry or ELISA.
  • T-regulatory suppression assays.
  • Custom configurations available for additional development and optimization cost.

Curia offers a wide variety of custom functional assays to test candidate therapeutics involved in various pathways:

  • Immune checkpoint blockade assays from PD-1/PD-L1, CTLA-4, and GITR pathways. Readout by Flow Cytometry or ELISA.
  • Custom cell-based, reporter-gene, or receptor-ligand assays.
  • Performed as transfer of an existing assay or developed as fully custom workflow.


Catalog # Name Timeline Price
1068 T-cell Stimulation Assay 3-4 weeks Request
1069 T-cell Proliferation Assay 3-4 weeks Request
1070 CMV Recall Assay 3-4 weeks Request
1071 Mixed Lymphocyte Reaction 3-4 weeks Request
1072 T-Reg Suppression Assay 3-4 weeks Request
1073 Custom Reporter Gene Assay 3-4 weeks Request
1074 Custom Cell-Based Assay 3-4 weeks Request
1075 Immune Checkpoint Bioassays 3-4 weeks Request
1076 Receptor-Ligand Blocking Assay 3-4 weeks Request
1077 Antibody-Mediated Viral Neutralization Assay 3-4 weeks Request